Apellis Pharmaceuticals Inc

Insider buying and a strong social‑media buzz signal confidence in Apellis Pharma’s Biogen merger, suggesting potential upside despite high P/E and clinical‑stage risk.

Biogen’s tender agreement with Apellis signals a potential takeover; insiders buy and sell shares, raising questions about the company’s future and investor strategy.

Apellis CEO’s recent 64,869‑share sale shows routine, tactical trading—little impact on stock, but a subtle hint of insider confidence for future clinical milestones.

Apellis CEO’s January 2026 share sale is a tax‑driven routine move, not a red flag—investors see strong analyst support and a resilient stock price.

Apellis insider selling spikes: execs offload 30 % of holdings amid a 21 % share drop, raising caution on future prospects and regulatory hurdles.

Apellis insider Watson David O. buys 888 shares at $14.95, betting on the company’s bullish rally and upcoming data from the J.P. Morgan Healthcare Conference.